CN101370480A - 含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物 - Google Patents

含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物 Download PDF

Info

Publication number
CN101370480A
CN101370480A CNA2007800030537A CN200780003053A CN101370480A CN 101370480 A CN101370480 A CN 101370480A CN A2007800030537 A CNA2007800030537 A CN A2007800030537A CN 200780003053 A CN200780003053 A CN 200780003053A CN 101370480 A CN101370480 A CN 101370480A
Authority
CN
China
Prior art keywords
water
pharmaceutical composition
weight
active ingredient
active component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800030537A
Other languages
English (en)
Chinese (zh)
Inventor
C·梅尔
K·诺伦伯格
A·格雷兹克
H-U·彼得莱特
J·德雷斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roehm GmbH Darmstadt
Original Assignee
Evonik Roehm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm GmbH filed Critical Evonik Roehm GmbH
Publication of CN101370480A publication Critical patent/CN101370480A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800030537A 2006-02-03 2007-01-17 含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物 Pending CN101370480A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006005485.7 2006-02-03
DE102006005485 2006-02-03

Publications (1)

Publication Number Publication Date
CN101370480A true CN101370480A (zh) 2009-02-18

Family

ID=38229086

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800030537A Pending CN101370480A (zh) 2006-02-03 2007-01-17 含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物

Country Status (13)

Country Link
US (1) US20090011007A1 (https=)
EP (1) EP1978936B1 (https=)
JP (1) JP2009525300A (https=)
KR (1) KR101387249B1 (https=)
CN (1) CN101370480A (https=)
BR (1) BRPI0707465B8 (https=)
CA (1) CA2641351C (https=)
ES (1) ES2427724T3 (https=)
IL (1) IL191604A (https=)
PL (1) PL1978936T3 (https=)
SI (1) SI1978936T1 (https=)
TW (1) TWI394584B (https=)
WO (1) WO2007090721A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755396A (zh) * 2019-12-06 2020-02-07 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297248A1 (en) * 2004-09-01 2010-11-25 Board Of Regents, The University Of Texas System Encapsulated particles for amorphous stability enhancement
US20100297251A1 (en) * 2004-09-01 2010-11-25 Board Of Regents, The University Of Texas System Encapsulated particles for enteric release
US20060045822A1 (en) * 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
CN101272769B (zh) * 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
PL382311A1 (pl) * 2007-04-27 2008-11-10 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
US8088451B2 (en) 2008-03-13 2012-01-03 Board Of Regents, The University Of Texas System Covalently functionalized particles for synthesis of new composite materials
CN103260609B (zh) * 2010-12-23 2017-08-11 雅培股份有限两合公司 基于固体分散体的固体延缓制剂
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
US20150011525A1 (en) * 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
ES2652266T3 (es) * 2012-04-02 2018-02-01 Pharma Seeds Create, Llc Composición sólida de dosificación oral de ibuprofeno que comprende un copolímero de ácido metacrílico
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
JP6052319B2 (ja) * 2015-03-25 2016-12-27 Ｎｔｔエレクトロニクス株式会社 動画像符号化装置
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US10532632B2 (en) 2016-06-30 2020-01-14 Emerson Climate Technologies, Inc. Startup control systems and methods for high ambient conditions
US10315495B2 (en) 2016-06-30 2019-06-11 Emerson Climate Technologies, Inc. System and method of controlling compressor, evaporator fan, and condenser fan speeds during a battery mode of a refrigeration system for a container of a vehicle
US10414241B2 (en) 2016-06-30 2019-09-17 Emerson Climate Technologies, Inc. Systems and methods for capacity modulation through eutectic plates
US10828963B2 (en) 2016-06-30 2020-11-10 Emerson Climate Technologies, Inc. System and method of mode-based compressor speed control for refrigerated vehicle compartment
US10569620B2 (en) 2016-06-30 2020-02-25 Emerson Climate Technologies, Inc. Startup control systems and methods to reduce flooded startup conditions
US10562377B2 (en) 2016-06-30 2020-02-18 Emerson Climate Technologies, Inc. Battery life prediction and monitoring
US10300766B2 (en) * 2016-06-30 2019-05-28 Emerson Climate Technologies, Inc. System and method of controlling passage of refrigerant through eutectic plates and an evaporator of a refrigeration system for a container of a vehicle
US10328771B2 (en) 2016-06-30 2019-06-25 Emerson Climated Technologies, Inc. System and method of controlling an oil return cycle for a refrigerated container of a vehicle
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
CN116744917A (zh) 2020-09-04 2023-09-12 礼蓝美国公司 适口调配物
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
JP7817300B2 (ja) * 2023-02-14 2026-02-18 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85058A1 (fr) * 1983-10-24 1985-06-19 Pharlyse Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
AT403988B (de) * 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
EP1125586A4 (en) * 1998-10-26 2003-06-11 Tanabe Seiyaku Co EXTENDED RELEASE PARTICLE
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
WO2004009059A1 (en) * 2002-07-19 2004-01-29 Aventis Pharma S.A. Taste masked oral composition of telithromycin
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110755396A (zh) * 2019-12-06 2020-02-07 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法
CN110755396B (zh) * 2019-12-06 2022-04-08 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法

Also Published As

Publication number Publication date
EP1978936A1 (de) 2008-10-15
TW200808357A (en) 2008-02-16
JP2009525300A (ja) 2009-07-09
IL191604A (en) 2013-05-30
BRPI0707465A2 (pt) 2011-05-03
KR20080090494A (ko) 2008-10-08
CA2641351A1 (en) 2007-08-16
BRPI0707465B8 (pt) 2022-07-05
EP1978936B1 (de) 2013-07-10
PL1978936T3 (pl) 2013-11-29
BRPI0707465B1 (pt) 2020-01-14
US20090011007A1 (en) 2009-01-08
IL191604A0 (en) 2008-12-29
CA2641351C (en) 2014-05-06
WO2007090721A1 (de) 2007-08-16
ES2427724T3 (es) 2013-10-31
TWI394584B (zh) 2013-05-01
KR101387249B1 (ko) 2014-05-21
SI1978936T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
CN101370480A (zh) 含有由聚合物和在水中溶解较差的活性成分组成的混合物的药物组合物
JP5193036B2 (ja) 低められたｐＨ‐値で作用物質を放出する薬剤形を製造するための被覆として、部分中和された陰イオン（メタ）アクリレートコポリマーの使用
JP5646340B2 (ja) ポリマー性対イオンと活性成分との塩
KR101387835B1 (ko) 코팅된 제약 제형을 제조하기 위한 중합체 혼합물의 용도및 혼합된 중합체성 코팅을 갖는 제약 제형
NL8601961A (nl) Granulaire vorm van farmaceutisch werkzame stoffen met vertraagde afgifte.
KR20100087011A (ko) 매트릭스형 의약 고형 제제
BRPI1010550B1 (pt) formas de dosagem, e, processo para a produção de preparações para formas de dosagem de substâncias ativas fracamente solúveis em água
CA2631498A1 (en) Hcv prodrug formulation
BG105325A (bg) Независещи от ефекта на храната многочастичкови фармацевтични препарати за продължително освобождаване и методи за получаването им
JP2018523691A (ja) Ｎ−ビニルピロリドン及びアクリル酸をベースとした水溶性ポリマーの医薬助剤としての使用
CN104510707A (zh) 一种泊沙康唑固体分散体及其制备方法
JP5758899B2 (ja) 活性物質を含有するコーティングにより被覆されたペレット
KR20230098278A (ko) 난용성 활성 약학 성분의 용해도를 향상시키기 위한 약학 조성물 및 방법
CN104721827A (zh) 一种难溶性抗真菌药物固体分散体及其制备方法
CA2812665C (en) Pharmaceutical composition for treating hcv infections
JPH0517371A (ja) 薬剤組成物
KR100663079B1 (ko) 이트라코나졸 함유 고체분산체의 제조방법
MX2008008915A (es) Composiciones farmaceuticas que comprenden mezclas de polimeros e ingredientes activos moderadamente solubles en agua
MX2008007428A (es) Formulacion de profamarcos para el virus de la hepatitis c
CN102781429A (zh) 经熔体涂覆的药物剂型
HK1167336A (en) Dronedarone solid dispersion and preparation method thereof
HK1167336B (en) Dronedarone solid dispersion and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20090218